Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    Farhat Nasim
    Farhat Nasim

      Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here

      • Home
      • Farhat Nasim

      Articles By : Farhat Nasim

      Lupin launches generic version of Lidex Ointment

      Lupin launches generic version of Lidex Ointment

      Farhat Nasim29 March 2019 1:18 PM IST
      Lupin's Fluocinonide Ointment USP, 0.05%, is the generic version of County Line Pharmaceuticals LLC's Lidex Ointment 0.05%. It is indicated for the...
      Dr Reddy

      Dr Reddy's launches Tadalafil Tablets to treat erectile dysfunction

      Farhat Nasim28 March 2019 12:06 PM IST
      Dr Reddy's Tadalafil tablets are available in four strengths including 2.5 mg, 5 mg, 10 mg, and 20 mg, each in 30-count bottle size.New Delhi: Dr...
      Clarus Therapeutics gets USFDA nod to Jatenzo for treatment of hypogonadism

      Clarus Therapeutics gets USFDA nod to Jatenzo for treatment of hypogonadism

      Farhat Nasim28 March 2019 11:23 AM IST
      The efficacy of Jatenzo was demonstrated in a four-month clinical trial involving 166 men with hypogonadism.New Delhi: The U.S. Food and Drug...
      Sandoz launches generic Treprostinil Injection

      Sandoz launches generic Treprostinil Injection

      Farhat Nasim27 March 2019 4:05 PM IST
      Sandoz will collaborate with RareGen, LLC to commercialize Treprostinil Injection, which is supplied in 20 mL multi-dose vials in four strengths –...
      Alembic Pharma gets USFDA nod to Tadalafil tablets for treating erectile dysfunction

      Alembic Pharma gets USFDA nod to Tadalafil tablets for treating erectile dysfunction

      Farhat Nasim27 March 2019 1:49 PM IST
      The approved product, Tadalafil tablets, is generic version of Eli Lilly and Company's Cialis tablet. New Delhi: Drug firm Alembic Pharmaceuticals...
      USFDA approves Novartis oral drug Mayzent to treat multiple sclerosis

      USFDA approves Novartis' oral drug Mayzent to treat multiple sclerosis

      Farhat Nasim27 March 2019 12:58 PM IST
      Mayzent is a synthetic derivative of Gilenya that has a similar way of working but which Novartis has modified to try to reduce side effects like a...
      JnJ, Bayer settles Xarelto lawsuits for 775 million Dollar

      JnJ, Bayer settles Xarelto lawsuits for 775 million Dollar

      Farhat Nasim27 March 2019 12:24 PM IST
      Lawsuits over Xarelto began piling up in 2014 and the companies had so far won all six trials over Xarelto's alleged bleeding risk.U.S: Bayer AG and...
      Manufacturers of SGLT2 inhibitor Drugs to have to INCLUDE safety WARNING in package: CDSCO

      Manufacturers of SGLT2 inhibitor Drugs to have to INCLUDE safety WARNING in package: CDSCO

      Farhat Nasim26 March 2019 1:28 PM IST
      New Delhi: Paying heed to the safety updates of Sodium-Glucose Cotransporter-2 (SGLT2) including medicines such as Canagliflozin, Dapagliflozin,...
      Lupin, YL Biologics gets PMDA approval for Etanercept biosimilar in Japan

      Lupin, YL Biologics gets PMDA approval for Etanercept biosimilar in Japan

      Farhat Nasim26 March 2019 10:00 AM IST
      "YL Biologics Ltd, a joint venture between Lupin's subsidiary Lupin Atlantis Holdings SA (LAHSA) and Yoshindo Inc in Japan, and Lupin (through its...
      Lupin gets USFDA nod to Sildenafil tablets to treat erectile dysfunction

      Lupin gets USFDA nod to Sildenafil tablets to treat erectile dysfunction

      Farhat Nasim26 March 2019 9:50 AM IST
      Sildenafil tablets are a phosphodiesterase-5 (PDE5) inhibitor indicated for the treatment of erectile dysfunction (ED). The product is a generic...
      Sun Pharma gets one observation from USFDA for Baska plant

      Sun Pharma gets one observation from USFDA for Baska plant

      Farhat Nasim26 March 2019 9:40 AM IST
      The Baska injectibles plant had recently filed for approvals to sell its products in the US, which is currently Sun Pharma's biggest market. The...
      OxyContin maker Purdue Pharma agrees to settle Oklahoma opioid case: Source

      OxyContin maker Purdue Pharma agrees to settle Oklahoma opioid case: Source

      Farhat Nasim26 March 2019 9:25 AM IST
      U.S: Purdue Pharma LP has agreed to settle a lawsuit by the state of Oklahoma accusing the OxyContin painkiller maker of helping fuel an opioid abuse...
      PrevNext

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok